Lecithin
Imagent (lecithin) is a small molecule pharmaceutical. Lecithin was first approved as Imagent on 2002-05-31. It is used to treat mental fatigue in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| debaochun | unapproved drug other | 2022-02-22 |
| jba joint revive | unapproved drug other | 2025-03-31 |
| the melanin skin protectant cream | unapproved drug other | 2025-05-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
174 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | 1 | 2 | 1 | 5 | 9 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | 2 | 1 | 5 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | — | 1 | 1 | 2 | 1 | 5 |
| Liver failure | D017093 | — | K72.9 | 1 | 2 | — | 1 | 1 | 4 |
| Hepatic insufficiency | D048550 | — | — | 1 | 2 | — | 1 | 1 | 4 |
| Hepatitis | D006505 | — | K75.9 | 1 | 1 | 1 | 2 | — | 4 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 1 | 1 | 2 | — | 4 |
| Hepatitis b | D006509 | — | — | — | — | — | 2 | 1 | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 2 | 3 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | 1 | 2 | 3 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | 1 | 1 | — | 9 | 14 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 3 | 4 | — | 1 | 7 |
| Colitis | D003092 | EFO_0003872 | K52.9 | — | 3 | 4 | — | 1 | 7 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 2 | 2 | — | 3 | 6 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 2 | 2 | — | 3 | 6 |
| Ulcer | D014456 | MPATH_579 | — | — | 2 | 4 | — | 1 | 6 |
| Covid-19 | D000086382 | — | U07.1 | — | 1 | 2 | — | 1 | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | 1 | — | 2 | 3 |
| Inflammation | D007249 | MP_0001845 | — | — | 1 | 1 | — | 2 | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | — | 1 | — | — | 7 | 8 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | 1 | — | — | 2 | 5 |
| Herpes simplex | D006561 | — | B00 | — | 4 | — | — | — | 4 |
| Herpes genitalis | D006558 | EFO_0007282 | A60 | — | 4 | — | — | — | 4 |
| Acute kidney injury | D058186 | — | N17 | 2 | 1 | — | — | — | 3 |
| Oxidative stress | D018384 | EFO_1001905 | — | — | 2 | — | — | 1 | 3 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 2 | — | — | — | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 2 | — | — | — | 2 |
| Proteinuria | D011507 | — | R80 | — | 2 | — | — | — | 2 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | — | 1 | — | — | 1 | 2 |
Show 33 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 4 | 5 |
| Child development | D002657 | — | — | 3 | — | — | — | — | 3 |
| Diet therapy | D004035 | — | — | 1 | — | — | — | — | 1 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | 1 | — | — | — | — | 1 |
| Autism spectrum disorder | D000067877 | — | F84.0 | 1 | — | — | — | — | 1 |
| Pervasive child development disorders | D002659 | EFO_0003756 | F84 | 1 | — | — | — | — | 1 |
| Blindness | D001766 | — | H53.12 | 1 | — | — | — | — | 1 |
| Retinitis pigmentosa | D012174 | — | H35.52 | 1 | — | — | — | — | 1 |
| Retinitis | D012173 | — | H30.9 | 1 | — | — | — | — | 1 |
Show 20 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Keratoconjunctivitis sicca | D007638 | EFO_1000906 | — | — | — | — | — | 4 | 4 |
| Dry eye syndromes | D015352 | — | H04.12 | — | — | — | — | 4 | 4 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | — | — | 4 | 4 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 4 | 4 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 3 | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Sjogren's syndrome | D012859 | EFO_0000699 | M35.0 | — | — | — | — | 2 | 2 |
| Growth disorders | D006130 | — | — | — | — | — | — | 2 | 2 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | — | — | 2 | 2 |
| Metabolism | D008660 | GO_0008152 | — | — | — | — | — | 2 | 2 |
Show 62 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lecithin |
| INN | perflubron |
| Description | Lecithin (/ˈlÉ›sɪθɪn/ LESS-ith-in; from the Ancient Greek λÎκιθος lékithos "yolk") is a generic term to designate any group of yellow-brownish fatty substances occurring in animal and plant tissues which are amphiphilic – they attract both water and fatty substances (and so are both hydrophilic and lipophilic), and are used for smoothing food textures, emulsifying, homogenizing liquid mixtures, and repelling sticking materials.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[N+](C)(C)CCOP(=O)([O-])OCC(COC=O)OC=O |
Identifiers
| PDB | — |
| CAS-ID | 93685-90-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL2107798 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | Q1D0Q7R4D9 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 34,843 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
322 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use